APP receives FDA approval to market Gemcitabine HCI for Injection.

APP will release this demonstration of Gemcitabine immediately. In January 2011, Teva Pharmaceuticals USA, Inc. Received approval and APP Pharmaceuticals released Gemcitabine HCI for Injection in the 200 mg and 1g dosage forms within a commercialization, manufacture and offer agreement with Teva. According to IMS Health data, 2010 branded revenue of most dosage strengths of Gemcitabine HCI for Injection in the United States were approximately $780 million. Sales of the generic 2 g dosage power accounted for $33.3 million, with 36,from November 2010 thru March 2011 000 units sold. ‘With the acceptance of the two 2 g dosage, APP becomes the just generic manufacturer to provide its customers all three dosage strengths of this critically important oncology medication,’ said John Ducker, Chief and President Executive Officer of APP Pharmaceuticals.Kaiser Family Foundation. Copyright 2007 Advisory Board Business and Kaiser Family Basis. All rights reserved.

Adults need help for mental, emotional health problem: Study In a comprehensive new study of mental health position and the use of mental health solutions by Californians, the UCLA Center for Health Policy Research discovered that nearly one in five adults in the condition – about 4.9 million people – stated they needed help for a emotional or mental health problem.